FinscoFinsco

CorMedix (US.CRMD)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CRMD · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion98.3%→
ROE8.8%↓
Cash Conversion110.5%↑
D/E Ratio0.33↓
Gross Margin82.5%↓
US.CRMD (CorMedix) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    98.3%    →
ROE                8.8%    ↓
Cash Conversion  110.5%    ↑
D/E Ratio          0.33    ↓
Gross Margin      82.5%    ↓
Key Metrics
US.CRMD (CorMedix) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 98.3% →
ROE 8.8% ↓
Cash Conversion 110.5% ↑
D/E Ratio 0.33 ↓
Gross Margin 82.5% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies